Screener
Palvella Therapeutics PVLA Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Palvella Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210463
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $9,334 | $4,074 |
| General and administrative | 5,521 | 3,797 |
| Total operating expenses | 14,855 | 7,871 |
| Operating loss | (14,855) | (7,871) |
| Other (expense) income: | ||
| Interest expense – royalty agreement | (2,039) | (1,215) |
| Fair value adjustments on derivative liabilities – royalty agreement | (116) | (75) |
Item 1. Financial Statements.
FAQ
- What is Palvella Therapeutics's other operating expenses?
- Palvella Therapeutics (PVLA) reported other operating expenses of $14.86M in Q1 2026.
- How has Palvella Therapeutics's other operating expenses changed year-over-year?
- Palvella Therapeutics's other operating expenses increased by 88.7% year-over-year, from $7.87M to $14.86M.
- What is the long-term trend for Palvella Therapeutics's other operating expenses?
- Over 2 years (2021 to 2025), Palvella Therapeutics's other operating expenses has grown at a -31.9% compound annual growth rate (CAGR), from $83.25M to $38.6M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about Palvella Therapeutics's other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude